Compassionate Use of Investigational New Drugs: Is the Current Process Effective? : Hearing Before the Committee on Government Reform, House of Representatives, One Hundred Seventh Congress, First Session, June 20, 2001
U.S. Government Printing Office, 2002 - Antineoplastic agents - 150 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
Abigail access to experimental ANN DAVIS approval process AstraZenica Barr Baxter breast cancer Burroughs BURTON cancer patients Chairman chemotherapy clinical trials colon cancer colorectal cancer Committee Compassionate Use IND compassionate use program David David's doctor DAVIS OF VIRGINIA DELANEY diagnosed disease drug available drug companies drug development early access programs effect efficacy expanded access experimental drugs experimental treatments facility FDA approval FDA's formulated prognosis frank disclosure give going Government Reform hearing hope hospice ImClone Systems important investigational drugs IRESSA issue Kellum life-threatening manufacturing months neck cancer needs oncologist oncology optimistic Orphan Drug OSI Pharmaceutical pessimistically discrepant phase physicians PMID prognoses protocol question requests safety Samuel Waksal Santino single patient IND sponsor survival estimates talking tell TEMPLE terminally ill testimony Thank things tients treated treatment IND tumor WAKSAL WELDON wife